Clinical Trial Update: A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03) [Phase 3]

View source ↗

Summary

A Phase III clinical trial evaluating Eque-cel for len-refractory relapsed/refractory multiple myeloma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Eque-cel

Snippet

Sponsor: Nanjing IASO Biotechnology Co., Ltd. | Conditions: Multiple Myeloma | Phase 3 | Status: RECRUITING